Log In Sign up
The largest database of trusted experimental protocols
> Anatomy > Body Part > System, Biliary

System, Biliary

The biliary system, also known as the biliary tract, is a network of ducts and organs responsible for the production, storage, and transportation of bile.
This system includes the gallbladder, hepatic ducts, and the common bile duct, which connects the liver and gallblader to the small intestine.
The biliary system plays a crucial role in the digestion and absorption of fats.
Disorders affecting the biliary system, such as gallstones, cholecystits, and bile duct cancer, can have significant impacts on overall health and wellbeing.
Reserch into the biliary system is critical for understanding its fuctions and developing effective treatments for related conditions.

Most cited protocols related to «System, Biliary»

1
Isolation of Normal Human Biliary Tissues
Adult human biliary tissues were dissected from intact livers and pancreases obtained but not used for transplantation into a patient. They were obtained through organ donation programs via United Network for Organ Sharing (UNOS). Those used for these studies were considered normal with no evidence of disease processes. Informed consent was obtained from next of kin for use of the tissues for research purposes, protocols received Institutional Review Board approval, and processing was compliant with Good Manufacturing Practice.
In addition, we received human fetal biliary tree and pancreata from an accredited agency (Advanced Biological Resources, San Francisco, CA) from fetuses between 16-20 weeks gestational age obtained by elective pregnancy terminations. The research protocols were reviewed and approved by the Institutional Review Board for Human Research Studies at the University of North Carolina at Chapel Hill. Further details on the samples are given in Tables S3 and S4.
The data given in all the figures and the pictures represent the findings in at least three independent experiments. For the rest of the methods, please see the online supplement.
Wang Y., Lanzoni G., Carpino G., Cui C.B., Dominguez-Bendala J., Wauthier E., Cardinale V., Oikawa T., Pileggi A., Gerber D., Furth M.E., Alvaro D., Gaudio E., Inverardi L, & Reid L.M. (2013). Biliary Tree Stem Cells, Precursors to Pancreatic Committed Progenitors: Evidence for Possible Life-long Pancreatic Organogenesis. Stem cells (Dayton, Ohio), 31(9), 1966-1979.
Publication 2013
Adult Bile Biopharmaceuticals Dietary Supplements Ethics Committees, Research Fetus Gestational Age Homo sapiens Induced Abortions Liver Organ Transplantation Pancreas Patients System, Biliary Tissues Transplantation
2
Establishment of Biliary Tract Cancer Cell Lines
Cell lines were established from pathologically proven primary biliary tract and ampulla of Vater cancer samples of six Korean patients. Of these, two cancer cell lines originated in extrahepatic bile duct cancer, one in intraheatic bile duct cancer, and one in adenocarcinoma of gall bladder, and two in ampulla of Vater cancer. Solid tumours were finely minced with scissors and disassociated into small aggregates by pipetting. Appropriate amounts of finely minced neoplastic-tissue fragments were seeded into 25 cm2 flasks. Tumour cells were initially cultured in ACL-4 medium supplemented with 5% heat-inactivated foetal bovine serum (AR5) (Park et al, 1987 (link), 1995 (link)). After establishment, cultures were maintained in RPMI 1640 supplemented with 10% heat- inactivated foetal bovine serum. If stromal-cell growth was noted in initial cultures, differential trypsinisation was used to obtain a pure tumour-cell population. Cultures were maintained in humidified incubators at 37°C in an atmosphere of 5% CO2 and 95% air. A-431, HeLa, and K-562 cell lines from the American Type Cell Culture (ATCC) and SNU-1 cell line from Korean Cell Line Bank (KCLB) were used for PCR controls. For growth properties and morphology study in vitro, population doubling times and cell viability were determined and cells grown on 75-cm2 culture flasks were observed daily by phase-contrast microscopy (Park et al, 1995 (link)).
Ku J.L., Yoon K.A., Kim I.J., Kim W.H., Jang J.Y., Suh K.S., Kim S.W., Park Y.H., Hwang J.H., Yoon Y.B, & Park J.G. (2002). Establishment and characterisation of six human biliary tract cancer cell lines. British Journal of Cancer, 87(2), 187-193.
Full text: Click here
Publication 2002
Adenocarcinoma Ampulla of Vater Atmosphere Cell Culture Techniques Cell Lines Cells Cell Survival Cholangiocarcinoma Culture Media Fetal Bovine Serum Gallbladder HeLa Cells Koreans Malignant Neoplasms Microscopy, Phase-Contrast Neoplasms Patients Stromal Cells System, Biliary Tissues
3
Diagnostic Criteria for Biliary Atresia

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Bile Biopsy Birth Cholangiography Cholestasis Congenital Abnormality Diagnosis Duct, Bile Fibrosis Gestational Age Icterus Infant Liver Liver Function Tests Operative Surgical Procedures Pathologists Patients Situs Ambiguus System, Biliary
4
Lenvatinib plus Pembrolizumab for uHCC
Study 116 is an ongoing phase Ib multicenter open-label study of lenvatinib plus pembrolizumab in patients with uHCC. The study consists of 2 phases: a dose-limiting toxicity (DLT) phase and an expansion phase. Patients received lenvatinib 12 mg (if bodyweight ≥ 60 kg) or 8 mg (if bodyweight < 60 kg) orally once daily and pembrolizumab 200 mg intravenously on day 1 of a 21-day treatment cycle (for up to 2 years after cycle 1 day 1). If no DLTs were reported in the DLT phase, the expansion phase would be initiated using the recommended dose from the DLT phase. Treatment was continued until disease progression, development of unacceptable toxicity, or withdrawal of consent. Additional details regarding continued pembrolizumab treatment are provided in the Appendix (online only).
Key inclusion criteria comprised the following: histologically or cytologically confirmed HCC (excluding fibrolamellar, sarcomatoid, and mixed cholangio-HCC tumors) or clinically confirmed HCC according to the American Association for the Study of Liver Diseases criteria; stage B (not suitable for transarterial chemoembolization) or C categorization based on the Barcelona Clinic Liver Cancer (BCLC) staging system; at least 1 measurable target lesion according to mRECIST per investigator assessment; Child-Pugh class A (score, 5-6); and Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1. Patients were excluded if they had clear invasion of the bile duct (classified clinically as a cholestatic type of HCC in which a patient’s initial manifestation is obstructive jaundice resulting from tumor thrombosis/compression/diffuse infiltration into the biliary tract); portal vein invasion with Vp426 (link); prior blood-enhancing treatment (including blood transfusion, blood products, or agents that stimulate blood cell production [eg, granulocyte colony-stimulating factor]) within 28 days before first dose of study drugs; prior treatment with lenvatinib or any anti–PD-1, anti–PD-L1, or anti–PD-L2 agent; and imaging findings with HCC having ≥ 50% liver occupation. Additionally, patients were excluded from the expansion phase if they had received prior systemic therapy for uHCC.
Written informed consent was provided by all patients before undergoing any study-specific procedures. The study protocol was approved by the relevant institutional review boards/independent ethics committees, and the study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines.
Finn R.S., Ikeda M., Zhu A.X., Sung M.W., Baron A.D., Kudo M., Okusaka T., Kobayashi M., Kumada H., Kaneko S., Pracht M., Mamontov K., Meyer T., Kubota T., Dutcus C.E., Saito K., Siegel A.B., Dubrovsky L., Mody K, & Llovet J.M. (2020). Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology, 38(26), 2960-2970.
Publication 2020
BLOOD Blood Cells Blood Transfusion Body Weight CD274 protein, human Child Cholestasis Disease Progression Duct, Bile Ethics Committees, Research Granulocyte Colony-Stimulating Factor Jaundice, Obstructive lenvatinib Liver Liver Function Tests Mixed Salivary Gland Tumor Neoplasms Patients pembrolizumab Portal System Sarcoma System, Biliary Therapeutics Thrombosis Veins, Portal
5
Cancer Trends and Projections in Korea
The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry, the Korea Central Cancer Registry (KCCR), in 1980. The history, objectives, and activities of the KCCR have been documented in detail elsewhere [3 (link)]. Incidence data from 1999 to 2016 were obtained from the Korea National Cancer Incidence Database (KNCI DB). Cancer cases were classified according to the International Classification of Diseases for Oncology, third edition [4 ], and converted according to the International Classification of Diseases, 10th edition (ICD-10) [5 ]. Mortality data from 1993 to 2017 were acquired from Statistics Korea [1 ]. The cause of death was coded and classified according to ICD-10 [5 ].
The cancer sites included in this study were (1) all cancers sites combined and (2) the 24 common cancer sites as follows: lips, oral cavity, and pharynx (C00-C14), esophagus (C15), stomach (C16), colon and rectum (C18-C20), liver and intrahepatic bile duct (liver) (C22), gallbladder and other parts of the biliary tract (gallbladder) (C23-C24), pancreas (C25), larynx (C32), trachea, bronchus and lung (lung) (C33-C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70-C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-C86, C96), multiple myeloma (C90), leukemia (C91-C95), and ‘other and ill defined’ sites.
Population data from 1993 to 2019 were obtained from the resident registration population data, reported by Statistics Korea. Data on the mid-year population, as of July 1 of the respective year, were analyzed. However, we used population data as of December 31, 2018 for the year 2019, because mid-2019 resident registration population data were not yet available at the time of analysis.
Linear regression models [6 ] were used to assess time trends and projections. We first performed a Joinpoint regression analysis on the data available to detect the year when significant changes occurred in cancer trends according to sex and cancer site. A Joinpoint regression describes changes in data trends by connecting several different line segments on a log scale at “joinpoints.” This analysis was performed using the Joinpoint software (ver. 4.3.1, http://surveillance.cancer.gov/joinpoint) from the Surveillance Research Program of the US National Cancer Institute [7 ]. For the analysis, we arranged to have at least four data points between consecutive joinpoints. Secondly, to predict age-specific cancer rates, a linear regression model was fitted to age-specific rates by 5-year age groups against observed years based on observed cancer incidence data of the latest trend. Finally, we multiply the projected age-specific rates by the age-specific population to get the projected cancer cases and deaths of the year 2019. For thyroid cancer, we used a square root transformation when fitting a linear regression model and converted the predicted values back to the original scale.
We summarized the results by using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. ASRs were standardized using the world standard population [8 ] and expressed per 100,000 persons.
Jung K.W., Won Y.J., Kong H.J, & Lee E.S. (2019). Prediction of Cancer Incidence and Mortality in Korea, 2019. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 51(2), 431-437.
Publication 2019
Age Groups Brain Breast Bronchi Carcinoma, Thyroid Central Nervous System Cervix Uteri Colon Esophagus Gallbladder Hodgkin Disease Intrahepatic Bile Duct Kidney Koreans Larynx Leukemia Lip Liver Lung Lymphoma, Non-Hodgkin, Familial Malignant Neoplasms Multiple Myeloma Neoplasms Oral Cavity Ovary Pancreas Pharynx Plant Roots Prostate Rectum Stomach System, Biliary Testis Thyroid Gland Trachea Urinary Bladder Uterus

Most recents protocols related to «System, Biliary»

1
Retrospective Study of A. caviae Infections
A retrospective study of 47 clinical A. caviae isolated from 46 patients with extra-intestinal infections from 2017 to 2020 at the First Medical Center of Chinese PLA General Hospital, a 3000-bed teaching hospital, was performed. Clinical data of 46 patients, including demographics, source of infection, underlying diseases, microbiological data, and respective outcomes, were retrieved from medical records. Diagnosis of bacteremia, biliary tract infection, urinary tract infection, pneumonia, and peritonitis was based on clinical, bacteriological, and radiological investigations.
Song Y., Wang L.F., Zhou K., Liu S., Guo L., Ye L.Y., Gu J., Cheng Y, & Shen D.X. (2023). Epidemiological characteristics, virulence potential, antimicrobial resistance profiles, and phylogenetic analysis of Aeromonas caviae isolated from extra-intestinal infections. Frontiers in Cellular and Infection Microbiology, 13, 1084352.
Full text: Click here
Publication 2023
Bacteremia Chinese Diagnosis Infection Intestines Patients Peritonitis Pneumonia System, Biliary Urinary Tract Infection X-Rays, Diagnostic
2
Characterizing Intrahepatic Cholangiocarcinoma Biomarkers
Samples were from 30 patients with iCCA, 17 samples with PSC, and 20 patients with other liver diseases but not iCCA or PSC seen at Mayo Clinic, Rochester, MN between January 2000 and May 2010. Peripheral blood was collected from each participant at the time of the office visit before treatment. Sera were stored at −80°C. The following data elements were abstracted from the medical record: demographics (age, gender, ethnicity, race, weight, height), medical history, etiology of liver disease, laboratory data including CA19-9 and AFP, and imaging results (ultrasound, CT, or MRI). Histopathology results and radiologic findings from the medical records of all patients were reviewed to ascertain the diagnosis of iCCA and identify tumor location. The diagnosis of iCCA in all patients was confirmed by histopathology. The anatomic location of CCAs was categorized as “intrahepatic” if the mass lesion arose within the hepatic parenchyma and did not extend to or involve the secondary branches of the biliary trees as demonstrated either by CT imaging, MRI, or endoscopic retrograde cholangiopancreatography findings. The etiology of liver disease was based on the laboratory, imaging, and histopathology results and the judgment of the treating physician. For patients with viral hepatitis, anti-HCV antibody, serum HCV RNA, HBV surface antigen, HBV e-antigen, and HBV DNA levels were recorded. Clinical information of the serum cohort is listed in Supplementary Fig. S2C.
Ochoa-Rios S., Blaschke C.R., Wang M., Peterson K.D., DelaCourt A., Grauzam S.E., Lewin D., Angel P., Roberts L.R., Drake R, & Mehta A.S. (2023). Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma. Cancer Research Communications, 3(3), 383-394.
Full text: Click here
Publication 2023
BLOOD CA-19-9 Antigen Congenital contractural arachnodactyly Diagnosis Endoscopic Retrograde Cholangiopancreatography Ethnicity Gender Hepatitis B e Antigens Hepatitis C Antibodies Hepatitis Viruses Liver Diseases Neoplasms by Site Office Visits Patients Physicians Serum Surface Antigens System, Biliary Ultrasonography Vision
3
Histological Assessment of Donor Bile Duct
For histological assessment, a cross-sectional sample of distal donor bile duct was taken at the end of cold ischemia just before liver implantation. Specimens were processed in 10% neutral buffered formalin and stained in hematoxylin and eosin. They were examined independently by 2 blinded hepatobiliary pathologists‚ and discrepancies in scores were resolved with multiheader consensus. Bile duct injury was scored using a bile duct injury scoring system as described by Op den Dries et al.4 (link) This is a semiquantitative systematic histological scoring system for bile duct injury that examines the biliary epithelium, mural stroma, vascular plexus, peribiliary glands, inflammation, bleeding‚ and thrombosis within bile duct samples. This histological scoring system has been shown to correlate with biliary complications.4 (link)Recipients were managed intraoperatively and postoperatively in the standard fashion at the ANLTU. Recipients were followed up for 24 mo‚ and medical records were comprehensively reviewed for outcome data. The clinical endpoint was biliary complications occurring within 24 mo from transplantation. Biliary complications were diagnosed by clinical or biochemical suspicion, and routine imaging was not performed because of low diagnostic yield in asymptomatic patients.15 (link) No threshold for liver biochemistry was used to trigger biliary investigation. Biliary complications included biliary strictures and bile leaks. Biliary strictures were defined as any narrowing of the donor biliary tree on magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography.16 (link),17 (link) Not all cases of biliary strictures underwent endoscopic retrograde cholangiopancreatography because of anatomic location or severity of clinical symptoms. Biliary strictures were subcategorized into anastomotic strictures (AS) and non-AS (NASs). AS was defined as strictures localized to the biliary anastomosis. NAS was defined as any stricture in the donor biliary tree away from the biliary anastomosis. Bile leak was defined as the presence of bilirubin in the posttransplant drain or extravasation of bile on biliary imaging.
This trial was prospectively registered on the Australian and New Zealand Clinical Trials Registry (U1111-1179-9801) and approved by the Sydney Local Health District Ethics Review Committee (Approval Number X15-0444).
Ly M., Lau N.S., McKenzie C., Kench J.G., McCaughan G., Crawford M, & Pulitano C. (2023). Does an Additional Bile Duct Flush With Low-viscosity Preservation Solution Reduce Bile Duct Injury? A Single-blinded Randomized Clinical Trial. Transplantation Direct, 9(3), e1443.
Publication 2023
Bile Bilirubin Blood Vessel Cholangiopancreatography, Magnetic Resonance Desiccation Diagnosis Donors Duct, Bile Endoscopic Retrograde Cholangiopancreatography Eosin Epithelium Formalin Inflammation Injuries Ischemia, Cold Liver Ovum Implantation Pathologists Patients Precipitating Factors Stenosis Surgical Anastomoses System, Biliary Thrombosis Transplantation
4
Germline ATM Variants Across Cancers
A comprehensive review of the peer-reviewed literature through MEDLINE was conducted using PubMed for articles published between 1970 and July 2022. Search keywords included “pathogenic,” “germline,” “ATM,” “variant,” “hereditary,” “cancer,” “gallbladder,” “uterus,” “duodenum,” “kidney,” “lung,” “epithelioid hemangioendothelioma,” and then later expanded to include “biliary tract,” “small bowel,” “ampulla,” and “sarcoma.” Keywords were connected by the Boolean functions AND and OR.
All cross-sectional studies involving thirty or more patients affected with cancer of the biliary tract, uterus, small intestine/ampulla, kidney, lung, or sarcoma, who had undergone hereditary cancer predisposition testing with a multigene panel, exome, or genome sequencing were considered for inclusion. Studies using redundant patient information drawn from large datasets were excluded from the review. The study text and supplemental information were reviewed for patient characteristics, total germline pathogenic variants detected, and specific germline ATM variants identified.
The prevalence for each cancer type was estimated by dividing the number of individuals with a germline ATM pathogenic variant by the total sample size. To estimate the prevalence among those with hereditary cancer susceptibility, the number of individuals with a germline ATM pathogenic variant was divided by the number of those testing positive for any pathogenic variant in a hereditary cancer gene.
Borja N.A., Silva-Smith R., Huang M., Parekh D.J., Sussman D, & Tekin M. (2023). Atypical ATMs: Broadening the phenotypic spectrum of ATM-associated hereditary cancer. Frontiers in Oncology, 13, 1068110.
Full text: Click here
Publication 2023
Biliary Tract Cancer Duodenum Epithelioid Hemangioendothelioma Exome Gallbladder Genetic Diversity Genetic Predisposition to Disease Genome Germ-Line Mutation Germ Line Intestines, Small Kidney Lung Malignant Neoplasms pathogenesis Patients Sarcoma System, Biliary Uterus
5
Causal Inference of Meat Intake and Digestive Cancers
We conducted a two-sample MR based on genome-wide association studies (GWAS) summary data to explore the causal relationship between the intake of five common meat types (processed meat, pork, beef, poultry, and lamb) and six common DTCs (esophageal, stomach, liver, biliary tract, and pancreatic cancers, and CRC). Pork, beef, and lamb are defined as “red meat” and poultry as “white meat.” To avoid sample overlap in exposure and outcome and interference from ethnic differences, we derived GWAS data for both exposure and outcome from the European population but from different cohorts.
Yun Z., Nan M., Li X., Liu Z., Xu J., Du X., Dong Q, & Hou L. (2023). Processed meat, red meat, white meat, and digestive tract cancers: A two-sample Mendelian randomization study. Frontiers in Nutrition, 10, 1078963.
Full text: Click here
Publication 2023
Beef Ditiocarb Europeans Fowls, Domestic Genome-Wide Association Study liposomal amphotericin B Liver Meat Pancreatic Cancer Pork Red Meat Stomach System, Biliary

Top products related to «System, Biliary»

1
21g chiba needle by Cook Medical
Sourced in United States
The 21G Chiba needle is a medical device used for various diagnostic and therapeutic procedures. It is a hollow, thin needle designed to precisely access and sample target tissues or fluids. The needle's core function is to facilitate minimally invasive procedures by providing a controlled and accurate way to reach specific anatomical locations.
2
Tjf 260v by Olympus
Sourced in Japan
The TJF-260V is a video duodenoscope designed for diagnostic and therapeutic procedures in the upper gastrointestinal tract. It features a slim, flexible insertion tube and a wide, forward-viewing field of view.
3
0.035 inch stiff guide wire by Cook Medical
Sourced in United States
The 0.035-inch stiff guide wire is a medical device designed to facilitate the insertion and positioning of catheters or other interventional devices within the human body. It is a thin, flexible wire with a stiff core, intended to provide support and guidance during medical procedures.
4
Jf 260v by Olympus
Sourced in Japan
The JF-260V is a laboratory equipment product manufactured by Olympus. It is a high-quality instrument designed for precise and reliable measurements in various scientific and research applications. The core function of the JF-260V is to provide accurate and reproducible results for the user's specific needs. Further details on the intended use or specific features of the product are not available within the scope of this request.
5
Collagenase 4 by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Sao Tome and Principe, Israel, Canada, Macao, Italy, Australia, Japan, Switzerland, Senegal
Collagenase IV is a purified enzyme used to dissociate and isolate cells from various tissue types. It is effective in breaking down collagen, a major structural component of the extracellular matrix.
6
2f11 antibody by Abcam
The 2F11 antibody is a mouse monoclonal antibody that recognizes an epitope on the human CD34 antigen. CD34 is a transmembrane glycoprotein that is expressed on the surface of hematopoietic stem and progenitor cells. The 2F11 antibody can be used for the identification and characterization of CD34-positive cells in various applications, such as flow cytometry and immunohistochemistry.
7
Sp8 light sheet confocal microscope by Leica
The Leica SP8 light-sheet confocal microscope is a versatile and high-performance imaging system. It combines the optical sectioning capabilities of confocal microscopy with the gentle illumination of light-sheet technology. The SP8 enables efficient fluorescence imaging of large, living specimens while minimizing phototoxicity.
8
Gf uct260 by Olympus
Sourced in Japan
The GF-UCT260 is a compact and versatile upright compound microscope designed for a variety of laboratory applications. It features a binocular viewing head, a quadruple nosepiece, and a built-in LED illumination system. The microscope offers high-quality optics and a durable metal frame construction.
9
Anti fade reagent by Agilent Technologies
Sourced in United States
The Anti-fade reagent is a laboratory solution designed to preserve and extend the fluorescence signal in fluorescence-based experiments. It is typically used in conjunction with fluorescent dyes or probes to prevent photobleaching and maintain the integrity of the fluorescent signal over time.

More about "System, Biliary"

The biliary system, also known as the biliary tract or hepatobiliary system, is a complex network of ducts and organs responsible for the production, storage, and transportation of bile.
This critical system includes the gallbladder, hepatic ducts, and the common bile duct, which connects the liver and gallbladder to the small intestine.
The biliary system plays a crucial role in the digestion and absorption of fats, making it essential for overall digestive health and wellbeing.
Disorders affecting the biliary system, such as gallstones, cholecystitis, and bile duct cancer, can have significant impacts on a person's health.
Research into the biliary system is critical for understanding its functions and developing effective treatments for these conditions.
Cutting-edge technologies like the 21G Chiba needle, TJF-260V endoscope, 0.035-inch stiff guide wire, and JF-260V duodenoscope are used to diagnose and treat biliary system disorders.
Additionally, Collagenase IV, 2F11 antibody, and the SP8 light-sheet confocal microscope are valuable tools for exploring the cellular and molecular aspects of the biliary system.
PubCompare.ai's AI-powered platform can optimize your biliary system research by helping you locate the best protocols from literature, preprints, and patents using intelligent comparisons.
This can enhance the reproducibility and accuracy of your findings, ultimately improving your research outcomes.
The GF-UCT260 duodenoscope and Anti-fade reagent are also useful resources for your biliary system investigations.
Experience the power of AI-driven insights and take your biliary system research to new heights with PubCompare.ai.